IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event

Rhea-AI Summary

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in investor relations events, including a fireside chat at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, at 2:15 PM ET. The discussion features CEO Yujiro Hata and is hosted by Li Watsek. Interested parties can access a live audio webcast through the IDEAYA website. The company focuses on precision medicine and synthetic lethality, aiming to develop targeted therapeutics using molecular diagnostics. IDEAYA emphasizes the importance of identifying patient populations most likely to benefit from its therapies.

SOUTH SAN FRANCISCO, Calif., April 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event(s).

Cantor's The Future of Oncology Virtual Symposium
Tuesday, April 4^th, 2023 at 2:15 PM ET

• Fireside chat with Yujiro Hata, Chief Executive Officer, hosted by Li Watsek, Vice President and Equity Research Analyst

A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on March 7, 2023 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-april-2023-investor-relations-event-301786510.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What is IDEAYA Biosciences participating in on April 4, 2023?

IDEAYA Biosciences will participate in Cantor's The Future of Oncology Virtual Symposium.

Who will be speaking at the investor relations event for IDYA on April 4, 2023?

CEO Yujiro Hata will speak during a fireside chat at the event.

How can I watch the IDEAYA investor relations event?

You can watch the live audio webcast on the IDEAYA website in the 'Investors/News and Events/Investor Calendar' section.

What is the focus of IDEAYA Biosciences?

IDEAYA is focused on precision medicine in oncology, particularly synthetic lethality and targeted therapeutics.

Where can I find more information about IDEAYA's business risks?

More information on business risks can be found in IDEAYA's recent Annual Report on Form 10-K filed on March 7, 2023.